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The introduction of a new quaternary ammonium compound, bretylium 
tosylate,' ,* which selectively blocks transmission in postganglionic sympathetic 
nerve fibers, may be an important advance in the treatment of hypertension and 
peripheral vascular diseases. Of equal interest is the opportunity it provides 
for the evaluation of the role of the sympathetic nervous system in the patho- 
genesis of these diseases. 
An attempt has been made, therefore, to study the ability of bretylium to 
block sympathetically mediated reflexes in man, and to determine the changes 
it produces in the circulation. The effect on the blood pressure after parenteral 
and oral administration has also been assessed. 
Methods 
The effects of bretylium tosylate2 have been studied in twenty patients (17 
hypertensives and 3 normotensives). Injections were made in small quan- 
tities, approximately 12.5 mg., until a dose of 100 mg. was given over a 10-min. 
period. Measurements have been made of skin temperature (11 subjects), 
digital blood flow (9 subjects), forearm blood flow (13 subjects), and cardiac 
output (5 subjects). The skin temperature measurements were made with 
thermocouples applied to the dorsum of the hand and foot and, on some occa- 
sions, another on the trunk. Finger blood flow measurements were made with 
a conventional air-filled plethysmograph applied to the terminal phalanx, with 
venous occlusion applied to the same digit. The forearm flow was measured 
by a Whitney mercury-in-rubber strain gauge: placed on the upper one third 
of the forearm, with venous occlusion applied by means of a sphygmomanom- 
eter cuff above the elbow. Another cuff a t  the wrist excluded the circulation 
from the hand. The room temperature in these studies varied from 72 to 76" F. 
Cardiac output was measured by the indicator dilution method using indo- 
cyanine green. Injections were made through a polyethylene catheter inserted 
approximately 10 cm. centrally through a venipuncture in the antecubital 
fossa. The arterial dilution curve was recorded from the brachial artery by a 
Gilfordt densitometer, which was calibrated with the known concentrations of 
dye in the patient's blood a t  the end of the procedure. 
In  10 other patients, the effect of oral medication on the blood pressure was 
also determined. Blood pressure levels were determined by averaging read- 
ings taken four times daily in the hospital, or by measurements made twice 
daily by the subject himself at home. 
Results 
Intravenous injections of doses of 12.5 mg. 
of bretylium tosylate resulted in an immediate but short-lived respiratory 
Characteristic e$ects of the drug. 
* Established Investigator of the American Heart Association, New York, N. Y. 
t Gilford Instrument Company, Oberlin, Ohio. 
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stimulation. This was accompanied by vasoconstriction of the skin (FIGURE l), 
which lasted 2 to 3 min. And sometimes a sharp elevation in blood pressure, 
of approximately 20/10 mm. Hg. followed. These changes recurred after 
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FIGURE 2. Effect of bretylium (100 mg. I.V.) on inspiratory reflex. The UYYOZU indicates 
onset of deep inspiration. 
sure elevation, some degree of sympathetic blockade could be demonstrated 
by a fall in blood pressure on standing. 
In three patients a rise in blood pressure occurred some 6 to 9 hours after 
the administration of the drug. Two had received the drug intravenously and 
one orally. In view of the time that had elapsed, it is impossible to be certain 
of a causal relationship between the rise in pressure and the administration of 
the drug, but no other explanation could be found for the increase in pressure 
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in any of the patients, and it exceeded the random variations in their blood 
pressure record. Reserpine (2.5 mg. I.M.) successfully reversed the rise in 
pressure. 
The degree of blockade was assessed by eliciting several constrictive reflexes. 
The reflex most readily abolished was the vasoconstriction produced in the 
finger after a deep inspiration (FIGURE 2). A dose of 100 mg. intravenously 
prevented this reflex response in six of the eight subjects studied. Similarly, 
the overshoot produced by the Valsalva maneuver was abolished in two sub- 
FIGURE 3. Effect of bretylium (100 mg. I.V.) on the Valsalva maneuver (hJt) and cold 
pressor test (right). 
jects (FIGURE 3). More potent reflexes were not completely suppressed. For 
example, the average rise in blood pressure produced by the standard cold 
pressor stimulus (FIGURE 3) was reduced from 55/38 to 30/18 mm. Hg. 
There were very few side effects produced by parenteral administration of 
bretylium; apart from the initial constrictive response, the only other effects 
were occasional flushing of the skin, nasal stuffiness, and injection of the con- 
junctivae. There were no alimentary or CNS effects. 
Ejects on the circulation. The most striking peripheral effect of bretylium 
was an increase in skin temperature of the hands and feet (FIGURE 4), which 
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averaged 1.50" F. for the former and 2.5" F. for the latter. There was no 
change in temperature of the trunk. In  association with this change there 
was an average increase of 35 per cent in finger blood flow. The forearm did 
not participate in this change. The average blood flow rate actually fell from 
5.0 to 4.7 m1./100 ml./min. 
The effects of bretylium on the circulation were compared with those of 
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tosylate intravenously to 17 hypertensive patients in the recumbent position 
resulted in a small fall in recumbent blood pressure, averaging 14/6 mm. Hg 
(TABLE 1). This was accompanied by a slight decrease in heart rate from 77 
to 74 beats/min. Records of blood pressure taken after the hemodynamic 
studies were complete showed a small increase in hypotensive effect with time, 
the maximal response averaging 22/14 mm. Hg (TABLE 1). The standing 
blood pressure showed a much greater reduction, with an average of 35/19 
mm. Hg. The diastolic fall is an estimate, since the response could not be 
recorded with accuracy in two patients. The average duration of effect of 
this dose of bretylium was 10 hours. 
TABLE 1
ON THE BLOOD PRESSURE IN 17 HYPERTENSIVES 
THE EFFECT OF A SINGLE INTRAVENOUS DOSE (100 MG. 1.v.) OF BRETYLIUM TOSYLATE 
Standing I ,  Recumbent 
Acute efiects (within 60 min.) 
Duration 
(hours) 


























Av. 196 (-14) 
Systolic Diastolic 
-15 -10 6 
-52 -30+ 8.5 
-40 -20 18 
- 30 -5 3 





















































































Only four patients showed a fall in pressure of 10 mm. Hg or more in systolic 
and diastolic levels in the recumbent position, and in one of these the fall was 
81/58 mm. Hg, reducing his pressure to 124/80 mm. Hg. This subject was 
also unusually sensitive to a ganglion-blocking agent. However when a sec- 
ond test with the same dose of bretylium was made some days later, the fall in 
pressure was only 12/8 mm. Hg, and the resulting level or “floor” of pressure 
was higher: 156/96 mm. Hg. 
Effects of oral medication. In 10 patients, studies of the effect of oral ad- 
ministration of bretylium showed that the effective dose varied from 600 to 
3200 mg./day. The average fall in pressure a t  optimum dosage was 11/13 
mm. Hg in the recumbent position, and 32/22 mm. Hg in the standing posi- 
tion (TABLE 2). 
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Standing 
(mm. Hr) 
The effect on the standing pressure was greater in the morning than in the 
evening. In  addition to dizziness, presumably usually related to orthostatic 
hypotension, several patients noticed a sensation of extreme fatigue on arising, 
which passed off in the course of the morning. Tolerance to the drug was 
noticed in the first 2 to 3 weeks of medication, but this was not troublesome 
since individual titration of dosage was required. Other side effects have con- 
sisted of nasal stuffiness, injection of the conjunctivae, and vague abdominal 
discomfort. 
Further studies to be reported elsewhere4 have shown that the effect of 
bretylium on the blood pressure is very similar to that achieved by ganglion 
blockers. Some patients who respond to one type of drug, however, may be 
resistant to the other. 




THE EFFECT OF ORAL ADMINISTRATION OF BRETYLIUM TOSYLATE 
























* Two pat 

















































120 j9o 6 
120/90 I 9160190 13
148/102 I 25 
(1 gm./day) throughout the period of the test. 
Conclusion 
The initial vasoconstrictor effects of bretylium are almost certainly the re- 
sult of local release of catecholamines, since they have been shown to occur 
after intra-arterial infusions of bretylium.' Lloyd Beck, in the Department 
of Pharmacology a t  the University of Michigan, has shown that the pressor 
response can be almost completely eliminated in dogs after reserpine has been 
used to deplete the peripheral stores of norepinephrine. The rise in pressure 
is also greatly enhanced by a ganglion-blocking drug. Furthermore, Beck 
has shown that the constrictive response may occur after the effect of direct 
sympathetic nerve stimulation has been blocked. This is an agreement with 
the clinical finding that postural hypotension may be elicited during the pressor 
response to the drug. I t  seems likely, therefore, that the release of norepi- 
nephrine is a peripheral effect occurring distally to the interruption of trans- 
mission in the sympathetic nerve fibers. 
Bretylium, in the dose used in this study, was adequate to block some con- 
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strictive re5exes, but the response to the cold pressor test was not abolished. 
Since bretylium does not block the output from the adrenal medulla, it is pos- 
sible that some sympatho-adrenal responses might remain even if the dose of 
the blocking agent were able to block neural transmission completely. The 
pattern of the changes in the peripheral circulation, manifested by an increase 
in flow to the hands and feet and little change in the forearm circulation, were 
similar to those observed with ganglion-blocking agents tetraethylamm~nium~ 
and hexamethonium.6 0' Apart from the initial vasoconstriction, bretylium 
did not appear to produce any effects that could not be attributed to blockade 
of sympathetic activity. For this reason it will be an invaluable tool in the 
study of the activity of the sympathetic nervous system in man, and will be of 
great value in assessing the activity of this system in hypertension. 
In  most recumbent hypertensive patients the fall in pressure caused by 
bretylium was negligible. Similarly, there was practically no change in heart 
rate. I n  those subjects in whom a fall in recumbent blood pressure occurred, 
a reduction in cardiac output was also observed. For the majority of hyper- 
tensives it seems unlikely that the sympathetic nervous system plays an im- 
portant role in the etiology of hypertension. An occasional patient was seen 
in whom an unexpectedly large fall in pressure occurred; these patients will 
require further study. 
The effect of oral medication, like that seen with parenteral administration, 
was mainly on the standing blood pressure. A small change was seen in the 
recumbent level, of magnitude similar to that seen after parenteral adminis- 
tration of the drug. The effective dose varied from 600 to 3200 mg./day. 
The drug produced a considerably greater effect on the blood on arising in the 
morning. Patients who have experienced 
low levels of pressure in the morning have either complained of dizziness and 
fainting, or of extreme lassitude. Since the blood pressure may fall to quite 
low levels without the presence of other warning side effects, this drug should 
be used with care in patients with cerebral or coronary artery disease. 
In  conclusion, bretylium provides a useful opportunity for the production 
of chemical sympathectomy in man which is symptomless if the patient re- 
mains in the recumbent position. On standing there is a profound fall in 
blood pressure. This action provides the basis for the use of bretylium in 
hypertension. Although the mode of action is nonphysiological and varies 
with posture throughout the day, it is, nevertheless, of great value in the treat- 
ment of patients with severe hypertension in whom simpler drugs, such as 
chlorothiazide and reserpine, have not effected an adequate reduction in pres- 
sure. 
The reason for this is unknown. 
Summary 
Bretylium tosylate in I.V. doses of 100 mg. produces blockade of some sym- 
pathetically mediated reflexes and a diminution of others. I t  results in an 
increase in blood flow to the hands and feet, but not to the forearm. The 
effect on the recumbent blood pressure is quite small, but marked postural 
hypotension always occurs. 
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Oral medication likewise produces its main effect on the standing pressure, 
and this is greater in the morning than evening levels. 
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